GlassScriptPhysician profile
Richard G Friedman
NPI 1881789196
$3,381.29
in general payments reported to CMS, 2019-2025
22 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $526 · 2021: $672 · 2022: $666 · 2023: $466 · 2024: $361 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $843.36 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $559.00 | 2019-2023 | Lifevest |
| Pfizer INC. | $263.19 | 2019-2024 | |
| Aop Health US, LLC | $223.35 | 2025 | Rapiblyk |
| Merck Sharp & Dohme LLC | $217.65 | 2021-2025 | Verquvo |
| Actelion Pharmaceuticals US, INC. | $189.95 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $155.67 | 2019-2025 | Farxiga, Andexxa |
| Abbott Laboratories | $142.55 | 2021-2024 | Aveir, Gallant |
| E.R. Squibb & Sons, L.L.C. | $141.89 | 2020-2025 | Camzyos, Eliquis |
| Philips North America LLC | $139.59 | 2022-2025 | (5044) Mcot, Mcot, (Ck4) Mcot |
| Janssen Pharmaceuticals, INC | $78.52 | 2019-2022 | |
| Baxter Healthcare | $62.13 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Cvrx, INC. | $57.50 | 2022-2023 | Barostim Neo System |
| Medtronic, INC. | $50.46 | 2024-2025 | Linq II, Mycarelink |
| Kestra Medical Technology Services, INC. | $43.35 | 2024 | Assure Wcd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.87 | 2020-2023 | Jardiance |
| Irhythm Technologies, INC. | $41.71 | 2022-2024 | Zio Monitor, Zio Xt Patch |
| Kiniksa Pharmaceuticals, LTD. | $37.02 | 2021-2022 | |
| Lilly USA, LLC | $25.54 | 2025 | Mounjaro |
| Coala Life INC | $22.70 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.56 | 2022 | |
| Sanofi-Aventis U.S. LLC | $20.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.